Translational Research Program Grant

The Translational Research Program Grant, offered by the Leukemia & Lymphoma Society, aims to expedite the transition of laboratory research into clinical applications for hematological malignancies. The program invites innovative proposals addressing prevention, diagnosis, or treatment methods based on cutting-edge research. For the 2025 cycle, applications must demonstrate in vivo proof of concept in relevant models, emphasizing the integration of scientific findings into practical treatments for blood cancers.

The goal of translational research is to reduce the time between laboratory findings and actual treatment.
Translational Research Program (TRP)
The Translational Research Program (TRP) was formed to enhance the transfer of basic research findings to clinical usefulness.
We are looking for applications that propose novel approaches to the prevention, diagnosis, or treatment of hematological malignancies and related pre-malignant conditions. Proposals should be based on molecular, cellular, or integrated systems findings and be conceptually innovative and with a clear plan for the eventual clinical translation of the studies proposed and the results expected.
The TRP Grant program is geared towards translational medicine for blood cancers. Earlier work in the translational environment has been funded in the past through the TRP mechanism, however, these types of projects would be a better fit for our Discovery Grant program and applicants are directed to apply under that mechanism.
For the 2025 application cycle we will only consider applications that adhere to the following submission guidelines:
For small molecule compounds the application must have in vivo proof of concept (POC) in appropriate mouse models.Alternatively, based on the mechanism of action, an in vitro POC with patient-derived samples may be considered.
For cellular or immunotherapies, in vivo POC would make for a stronger application.